ABEONA THERAPEUTICS INC. ABEO
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
-5.75
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $5.8M | $71.2M | — | -$84.3M | $159.2M |
| 2024 | — | -$63.7M | — | -$58.5M | $44.0M |
| 2023 | $3.5M | -$54.2M | — | -$37.3M | $14.8M |
| 2022 | $1.4M | -$39.7M | — | -$43.6M | $26.8M |
| 2021 | $3.0M | -$84.9M | — | -$69.8M | $42.4M |
| 2020 | $10.0M | -$84.2M | — | -$36.4M | $102.6M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -5.75 (distress)
- Working capital / assets 0.799
- Retained earnings / assets -3.38
- EBIT / assets -0.407
- Equity / liabilities 2.638
Source: SEC EDGAR filings · CIK 0000318306 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.